Literature DB >> 15757941

Medicaid policies to contain psychiatric drug costs.

Chris Koyanagi1, Sandra Forquer, Elaine Alfano.   

Abstract

This study reviews Medicaid policies to restrict access to psychiatric medications. Policies on prior authorization, preferred drug lists, limitations on the number of prescriptions, fail-first requirements, and use of generics are reviewed. All states apply one or more of those policies to medications for mental illness, and many apply several. A large number of states have legislated exemptions from those policies for certain medications, particularly antipsychotics and antidepressants. Other psychiatric medications are less well protected. Some states appear to restrict access severely. Questions have been raised as to whether these policies actually save money in the long term.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15757941     DOI: 10.1377/hlthaff.24.2.536

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  12 in total

1.  Improving psychotherapeutic medication prescribing in Florida: implementation of the Florida Medicaid Drug Therapy Management Program (MDTMP).

Authors:  Robert J Constantine; Marie A McPherson; Mary Elizabeth Jones; Rajiv Tandon; Edmund R Becker
Journal:  Community Ment Health J       Date:  2012-03-01

2.  Treatment for ADHD: is more complex treatment cost-effective for more complex cases?

Authors:  E Michael Foster; Peter S Jensen; Michael Schlander; William E Pelham; Lily Hechtman; L Eugene Arnold; James M Swanson; Timothy Wigal
Journal:  Health Serv Res       Date:  2007-02       Impact factor: 3.402

3.  Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia.

Authors:  Mark Olfson; Tobias Gerhard; Cecilia Huang; Jeffrey A Lieberman; William V Bobo; Stephen Crystal
Journal:  Schizophr Bull       Date:  2011-02-09       Impact factor: 9.306

4.  Preparing to implement medication algorithms: staff perspectives and system infrastructure.

Authors:  Jennifer P Wisdom; Sarann Bielavitz; Bentson McFarland; Jon C Collins; Ann Hamer; Dean Haxby; David A Pollack
Journal:  J Psychiatr Pract       Date:  2008-07       Impact factor: 1.325

5.  Tying comparative effectiveness information to decision-making and the future of comparative effectiveness research designs: the case for antipsychotic drugs.

Authors:  Anirban Basu; Herbert Y Meltzer
Journal:  J Comp Eff Res       Date:  2012-03       Impact factor: 1.744

6.  Prior authorization for antidepressants in Medicaid: effects among disabled dual enrollees.

Authors:  Alyce S Adams; Fang Zhang; Robert F LeCates; Amy Johnson Graves; Dennis Ross-Degnan; Daniel Gilden; Thomas J McLaughlin; Christine Lu; Connie M Trinacty; Stephen B Soumerai
Journal:  Arch Intern Med       Date:  2009-04-27

7.  Improving quality and diffusing best practices: the case of schizophrenia.

Authors:  Marcela Horvitz-Lennon; Julie M Donohue; Marisa E Domino; Sharon-Lise T Normand
Journal:  Health Aff (Millwood)       Date:  2009 May-Jun       Impact factor: 6.301

8.  Patterns of atypical antipsychotic subtherapeutic dosing among Oregon Medicaid patients.

Authors:  Daniel M Hartung; Jennifer P Wisdom; David A Pollack; Ann M Hamer; Dean G Haxby; Luke Middleton; Bentson H McFarland
Journal:  J Clin Psychiatry       Date:  2008-10       Impact factor: 4.384

9.  Disparities in antidepressant use in pregnancy.

Authors:  A Yamamoto; M C McCormick; H H Burris
Journal:  J Perinatol       Date:  2014-11-20       Impact factor: 2.521

10.  State policy influence on the early diffusion of buprenorphine in community treatment programs.

Authors:  Lori J Ducharme; Amanda J Abraham
Journal:  Subst Abuse Treat Prev Policy       Date:  2008-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.